A Disintegrin And Metalloproteinase
From Proteopedia
(Difference between revisions)
Line 8: | Line 8: | ||
* '''ADAM17''' (TACE or TNF-α converting enzyme) processes the tumor necrosis factor-α.<br /> | * '''ADAM17''' (TACE or TNF-α converting enzyme) processes the tumor necrosis factor-α.<br /> | ||
* '''ADAM33''' is implicated in asthma.<br /> | * '''ADAM33''' is implicated in asthma.<br /> | ||
- | * '''ADAMTS''' is ADAM with thrombospondin motifs. <br /> | + | * '''ADAMTS''' is ADAM with thrombospondin motifs<ref>PMID:15554875</ref>. <br /> |
* '''ADAMTS1''' has anti-angionenic activity. <br /> | * '''ADAMTS1''' has anti-angionenic activity. <br /> | ||
* '''ADAMTS4''' and '''ADAMTS5''' are involved in the degradation of aggrecan.<br /> | * '''ADAMTS4''' and '''ADAMTS5''' are involved in the degradation of aggrecan.<br /> |
Revision as of 10:24, 19 May 2024
|
References
- ↑ Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J. 2005 Feb 15;386(Pt 1):15-27. PMID:15554875 doi:10.1042/BJ20040424
- ↑ Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008, Aug 15. PMID:18762209 doi:http://dx.doi.org/10.1016/j.mam.2008.08.001
- ↑ Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 2009;15(20):2288-99. PMID:19601831 doi:10.2174/138161209788682442
- ↑ Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319-35. PMID:19601834 doi:10.2174/138161209788682398
- ↑ Sleziak J, Gawor A, Błażejewska M, Antosz K, Gomułka K. ADAM33's Role in Asthma Pathogenesis: An Overview. Int J Mol Sci. 2024 Feb 15;25(4):2318. PMID:38396994 doi:10.3390/ijms25042318